The MCUR1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population originating from the Raji human Burkitt lymphoma B lymphocyte line. This heterogeneous pool contains cells with targeted disruptions in the MCUR1 gene, providing a robust loss-of-function model free from clonal bias. Researchers can leverage this system to investigate mitochondrial calcium signaling and associated metabolic pathways in a cancer-relevant background.
Raji cells are Epstein-Barr virus (EBV)-positive B lymphocytes derived from a Burkitt lymphoma patient. They grow in suspension and lack surface immunoglobulin, characteristics that define their utility as a cancerous B cell model. Although part of the adaptive immune lineage, Raji cells are non-antibody-producing and are extensively employed in lymphoma research, drug screening, and studies of viral oncogenesis. Their transformed state offers a platform to examine how mitochondrial homeostasis intersects with lymphoma cell survival.
MCUR1 encodes a scaffold protein that stabilizes the mitochondrial calcium uniporter (MCU) complex, a critical gateway for mitochondrial Ca2+ uptake. MCUR1 directly binds MCU and EMRE, and its activity is modulated by the Ca2+-sensing regulators MICU1 and MICU2, which respond to cytosolic Ca2+ levels and mitochondrial membrane potential. At endoplasmic reticulum (ER)-mitochondria contact sites, MCUR1 facilitates Ca2+ influx through channels composed of IP3R, VDAC, and GRP75. Once inside the mitochondrial matrix, Ca2+ activates pyruvate dehydrogenase (PDH) and other TCA cycle enzymes, boosting oxidative phosphorylation and ATP synthesis. This process simultaneously regulates reactive oxygen species (ROS) production and cytochrome c release, thereby influencing apoptotic cascades and signaling through AMPK and mTOR pathways.
In the Raji lymphoma context, MCUR1 knockout is expected to destabilize MCU complexes, attenuate mitochondrial Ca2+ import, and reduce TCA cycle flux and ATP output, likely sensitizing these cells to apoptotic triggers. Given the involvement of MCUR1 in diverse cancers such as hepatocellular carcinoma, breast cancer, and colorectal cancer, this model permits mechanistic dissection of mitochondrial calcium signaling in Burkitt lymphoma. It also enables synthetic lethality screens and preclinical evaluation of MCU-targeted therapeutics aimed at exploiting metabolic vulnerabilities in B cell malignancies.
These polyclonal knockout cells are well-suited for mitochondrial Ca2+ imaging using Rhod-2 AM, bioluminescent ATP measurement, Seahorse metabolic flux analysis, and Annexin V apoptosis assays. They support biochemical analysis of the MCU complex via co-immunoprecipitation and Western blotting, as well as transcriptomic profiling by RT-qPCR or RNA-seq. Researchers investigating cancer metabolism, bioenergetics, or mitochondrial pharmacology can employ this tool for drug screening against MCU modulators and for modeling B-cell lymphoma. For further technical information, please contact Ascent Research.
